Evidence map›Paper›PMID 35357901›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2022

Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index.

N George Mikhaeel, Martijn W Heymans, Jakoba J Eertink, Henrica C W de Vet, Ronald Boellaard, Ulrich Dührsen, Luca Ceriani, Christine Schmitz, Sanne E Wiegers, Andreas Hüttmann and 6 more

Abstract read
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. BMC medical imaging · 2026
    Article
  13. Article
  14. Article
  15. Validation of an AI Method for Automated Lymphoma Metabolic Tumor Volume Segmentation Using a Public Benchmark PET/CT Dataset.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

N George MikhaeelDepartment of Clinical Oncology, Guy's Cancer Centre and School of Cancer and Pharmaceutical Sciences, King's College London University, London, United Kingdom.ORCID 0000-0003-0359-0328
Martijn W HeymansAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.ORCID 0000-0002-3889-0921
Jakoba J EertinkAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-6094-0016
Henrica C W de VetAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.ORCID 0000-0002-5454-2804
Ronald BoellaardAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Ulrich DührsenDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-4034-9472
Luca CerianiDepartment of Oncology, IOSI-Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland.
Christine SchmitzDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sanne E WiegersAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-3698-8121
Andreas HüttmannDepartment of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0003-2230-3873
Pieternella J LugtenburgDepartment of Hematology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands.ORCID 0000-0002-6735-8651
Emanuele ZuccaDepartment of Oncology, IOSI-Oncology Institute of Southern Switzerland, Bellinzona; Università della Svizzera Italiana, Bellinzona, Switzerland.
Gerben J C ZwezerijnenAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0002-9571-9362
Otto S HoekstraAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Cancer Center Amsterdam, Amsterdam, the Netherlands.
Josée M ZijlstraAmsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, the Netherlands.ORCID 0000-0003-1074-5922
Sally F BarringtonKing's College London and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's Health Partners, Kings College London, London, United Kingdom.ORCID 0000-0002-2516-5288

Funding

Cancer Research UKDepartment of Health RP-2-16-07-001Medical Research CouncilWellcome Trust 203148/Z/16/ZWellcome Trust WT203148/Z/16/Z
6 · The paper itself

Abstract

purposeBaseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model.

methodsPET scans and clinical data were included from five published studies in newly diagnosed diffuse large B-cell lymphoma. Transformations of MTV were compared with the primary end points of 3-year progression-free survival (PFS) and overall survival (OS) to derive the best relationship for further analyses. MTV was compared with IPI categories and individual components to derive the best model. Patients were grouped into three groups for survival analysis using Kaplan-Meier analysis; 10% at highest risk, 30% intermediate risk, and 60% lowest risk, corresponding with expected clinical outcome. Validation of the best model was performed using four studies as a test set and the fifth study for validation and repeated five times.

resultsThe best relationship for MTV and survival was a linear spline model with one knot located at the median MTV value of 307.9 cm

conclusionA new prognostic index is proposed using MTV, age, and stage, which outperforms IPI and enables individualized estimates of patient outcome.

Indexed as

Lymphoma, Large B-Cell, DiffuseDisease-Free SurvivalFluorodeoxyglucose F18HumansPositron-Emission TomographyPrognosisRetrospective StudiesTumor BurdenFluorodeoxyglucose F18

Identifiers

PMID35357901
PMCPMC9287279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.